{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-032272","form_type":"8-K","ticker":"ENSC","cik":"0001716947","company_name":"Ensysce Biosciences, Inc.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.244458+00:00","generated_at":"2026-05-31T09:22:23.158243+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Ensysce Biosciences Q2 2024 net loss $2.0M; PF614-MPAR Phase 1b and OUD candidate PF9001 advance","bullets":["Net loss attributable to common stockholders was $2.0M in Q2 2024 vs $2.2M in Q2 2023.","Cash and cash equivalents totaled $1.0M at June 30, 2024, down from $1.1M at year-end 2023.","R&D expense fell to $0.9M from $1.6M YoY, driven by lower clinical and pre-clinical costs.","PF614-MPAR Phase 1b study (PF614-MPAR-102) progressing with Quotient Sciences; overdose protection verification planned.","PF9001 selected as lead OUD candidate in June; supported by NIH/NIDA HEAL award up to $15M."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-032272","json":"https://secwatch.observer/filing/0001493152-24-032272.json","markdown":"https://secwatch.observer/filing/0001493152-24-032272.md","text":"https://secwatch.observer/filing/0001493152-24-032272.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716947/000149315224032272/0001493152-24-032272-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716947/000149315224032272/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:22:23.158243+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}